Biomarkers Market by Product (Consumable, Service), Type (Safety, Efficacy, Validation), Disease (Cancer (Solid & Liquid Biopsy), Neurological), Application (Diagnostics, Drug Discovery & Development, Personalized Medicine) - Global Forecast to 2026
[238 Pages Report] The global biomarkers market is projected to reach USD 78.1 billion in 2026 from USD 43.1 billion in 2021 at a CARG of 12.6%. Growth in the biomarkers market is mainly driven by factors such as the growing importance of companion diagnostics, increasing prevalence of cancer worldwide, increasing funds & grants for biomarker research, and continuous product innovations.
To know about the assumptions considered for the study, Request for Free Sample Report
COVID-19 Impact on the Global Biomarkers Market
COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 has moved from a regional crisis to a global pandemic. The World Health Organization (WHO) officially declared the outbreak of COVID-19 a pandemic.
A study conducted by Diaceutics PLC (UK) on tracking the diagnosis and biomarker testing rates for specific cancer types suggested that in the US market, the newly diagnosed metastatic non-small cell lung cancer patient volumes declined over 30% from February of 2020 to March 2020. This stark drop in just one month also impacted the rates of KRAS, BRAF and EGFR testing, which are key biomarkers supporting the appropriate selection of precision medicine therapies that benefit certain patients. Specifically, nearly 4,000 fewer EGFR tests were performed in the month when most of the country initiated strict “stay-at-home” orders, representing a 13% drop from the previous month. Declines were also seen in colorectal cancer (14% lower), acute myeloid leukemia (also 14% lower), breast cancer (8.4% lower) and ovarian cancer (8.6% lower).
On the other hand, many biomarkers are also playing an important role in the diagnosis of COVID-19. Biomarkers such as C-reactive protein, serum amyloid A, interleukin-6, lactate dehydrogenase, neutrophil-to-lymphocyte ratio, D-dimer, cardiac troponin, renal biomarkers, lymphocytes and platelet count. These markers showed significantly higher levels in patients with severe complications of COVID-19 infection compared to their non-severe counterparts. Lymphocytes and platelet count showed significantly lower levels in severe patients compared to non-severe patients.
Additionally, the leading players in this market also developed various tests and assay kits to support COVID-19 research. The following are some related examples:
|
Company |
Nature of Development |
Segment |
Product |
|
Thermo Fisher Scientific, Inc. (U.S.) |
Product Launch |
Consumables |
TaqCheck SARS-CoV-2 Fast PCR Assay |
|
F. Hoffmann-La Roche Ltd (Switzerland) |
Product Launch |
Consumables |
Elecsys Anti-SARS-CoV-2 antibody test |
|
Abbott (U.S.) |
Product Launch |
Consumables |
Abbott ID NOW COVID-19 test and Abbott m2000 RealTime SARS-CoV-2 EUA test |
|
QIAGEN N.V. (Netherlands) |
Product launch |
Consumables |
NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Test |
The development of such innovative biomarker technologies and a wide range of products such as antibody tests and PCR tests used in the COVID-19 research have helped researchers to untangle the complex picture of coronavirus, and hence the COVID-19 has positively impacted the biomarkers market.
Biomarkers Market Dynamics
Driver: Growing importance of companion diagnostics
Companion diagnostics and biomarkers have become increasingly relevant in the practice of medicine, leading to improved diagnosis, treatment, and monitoring across several disease areas. It can be used to identify patients likely to respond well to certain drugs or treatment options. These diagnostics are often used in conjunction with a specific drug. For instance, the Oncomine Dx Target Test (Thermo Fisher Scientific, Inc.) helps in biomarker testing of non-small cell lung cancer (NSCLC) patients eligible for ROZLYTREK (entrectinib).
For the development of companion diagnostics, pharmaceutical companies are often partners of choice. For instance,
Recent Developments in Companion Diagnostics
Month & Year |
Deal Type |
COMPANY name 1 |
company |
Description |
|
May 2021 |
Partnership |
QIAGEN N.V. (Netherlands) |
Mirati Therapeutics Inc. (U.S.) |
The company partnered with Mirati Therapeutics to develop KRAS-G12C companion diagnostic for Non-Small Cell Lung Cancer (NSCLC). The new companion diagnostic will expand QIAGEN’s therascreen KRAS testing portfolio. |
|
November 2020 |
Collaboration |
QIAGEN N.V. (Netherlands) |
BioNTech S.E. (Germany) |
The company collaborated with BioNTech to develop and commercialize a tissue-based companion diagnostic (CDx) to be used with investigational cancer treatment BNT113 – which identifies patients with human papillomavirus (HPV) associated squamous cell carcinoma of the head and neck (SCCHN). The company also plans to expand the panel for use across HPV-driven cancers such as cervical cancer and other cancers to provide a universal HPV CDx for their pharmaceutical partners. |
|
July 2020 |
Agreement |
Thermo Fisher Scientific, Inc. (U.S.) |
Chugai Pharmaceutical Co., Ltd. (Japan) |
The company signed a companion diagnostic agreement with Chugai Pharmaceutical to expand the use of the Oncomine Dx Target Test and expedite local biomarker testing of non-small cell lung cancer (NSCLC) patients eligible for ROZLYTREK (entrectinib) treatment in Japan. |
Companion diagnostics has significant potential, with an increase in the demand for high-priced specialized therapies and the demand for safer & more effective drugs. Biomarkers play an important role in the development of companion diagnostics with their ability to identify drug target molecules. Thus, the growing importance of companion diagnostics will drive the biomarkers market.
Restraint: High capital investments and lengthy timelines for biomarker development
Validating biomarkers is a lengthy process owing to the inconsistency in its performance in disease diagnosis. Due to this, the validation process becomes time-consuming (approximately 15 years together with the time needed for FDA approval) as well as expensive. Different categories of biomarkers tend to share common development and validation process phases, and therefore the process and timeline to develop and validate biomarkers are similar across biomarker categories, with a few differences. One difference is the longer length of time needed for the clinical validation and utility phase for prognostic biomarkers and surrogate endpoints, compared to predictive and safety biomarkers. Development and validation are most costly for surrogate endpoints, mostly in clinical trials, due to the extensive clinical validation needed.
Opportunity: Personalized medicine
Biomarkers play a key role in personalized medicine, with applications including diagnosis, prognosis, and selection of targeted therapies. Over the years, personalized medicine has gained recognition due to the various limitations of standard diagnosis and treatment procedures. Many areas of medicine, from cancer to immunological disorders, are moving towards tailored treatment for individual patients based on their genetic signatures and clinical characteristics. Personalized medicine is used to identify the most beneficial treatment path for individual patients. The use of biomarkers plays a very important role in certain aspects of personalized medicine. Consumables used in biomarker testing enable the identification of these diseases. Biomarker diagnostic products are also used as companion diagnostics for several investigational therapies.
Additionally, advances in genomics have spurred a better understanding of certain types of cancer, allowing for the development of precision therapies based on a specific gene mutation or molecular target, which can give patients better options to treat their cancer. Biopharmaceutical researchers have focused on identifying biomarkers, for example, the HER2 positive gene mutation—for women with breast cancer. These mutations may be passed from generation to generation and can help predict a patient’s risk of developing certain cancers. By tailoring treatments using biomarkers, health care providers can deliver the most personalized benefit to each patient.
Challenge: Challenges associated with biomarker validation
The biomarker validation process includes the evaluation of assays or measurement of performance characteristics such as sensitivity, specificity, and reproducibility. Validation is critical for establishing biomarkers as reliable tools to support development, medical care, and biopharma investment decisions. However, the high costs involved in biomarker validation are a major concern for companies, especially small organizations. Furthermore, factors such as the inherent variability in biomarker levels and molecular heterogeneity pose additional challenges in the biomarker validation process. Another challenge is the length of time required for assay development, due to which the ability to develop assays does not keep pace with the ability to generate biomarkers.
The use of biomarker-based tests in clinical settings requires evidence of the biomarker’s clinical validity and utility. This is important not just to help physicians in their decision-making process within the practice of evidence-based medicine but also to gain regulatory approvals and appropriate reimbursements for the test. However, collecting the data necessary to show clinical validity and utility may be a time-consuming and expensive process, which is further complicated by the lack of standards. There are also questions regarding sharing, protecting, and analyzing data. All these factors may pose a major challenge for the biomarkers market.
By product & service segment, the consumables segment accounted for the largest share of the biomarkers market in 2020.
By product, the biomarkers market is segmented into consumables, services, and software. In 2020, the consumables segment accounted for the largest share of the global biomarkers market. The large share of this segment can primarily be attributed to the increasing use of kit-based products for biomarker testing and the repeated purchase of consumables.
By type, the efficacy biomarkers segment accounted for the largest share of the biomarkers market in 2020.
Based on type, the biomarkers market is segmented into efficacy biomarkers, safety biomarkers, and validation biomarkers. In 2020, the efficacy biomarkers segment accounted for the largest share of the global biomarkers market. The large share of this segment can be attributed to the ability of these biomarkers to evaluate the therapeutic efficacy of drug products.
By disease indication, infectious diseases segment accounted for the largest share of the biomarkers market in 2020.
Based on disease indication, the biomarkers market is segmented into cancer, infectious diseases, neurological disorders, immunological disorders, cardiovascular disorders, and other disease indications. In 2020, the infectious diseases segment accounted for the largest share of the biomarkers market. The large share of this segment can be attributed to the growing prevalence of infectious diseases, coupled with the outbreak of the COVID-19 pandemic.
By application, the diagnostics application segment accounted for the largest share of the biomarkers market in 2020.
Based on application, the biomarkers market is segmented into diagnostics, drug discovery & development, personalized medicine, disease risk assessment, and other applications. In 2020, the diagnostics segment accounted for the largest share of the application segment in the biomarkers market. The use of biomarkers for the diagnosis of multiple diseases, including cancer, infectious diseases, cardiovascular disorders, and neurological disorders, is on the rise. The increasing use of biomarkers is a major factor that drives the growth of the diagnostics segment of the biomarkers market.
North America accounted for the largest share of the biomarkers market in 2020.
In 2020, North America accounted for the largest share of the market. The large share of this region can be attributed to the growing use of biomarkers in personalized medicine, various growth strategies adopted by key players with established pharmaceutical companies in this region, and a higher adoption rate of biomarkers for disease diagnostics, majorly in cancer diagnosis.
To know about the assumptions considered for the study, download the pdf brochure
The biomarkers market is dominated by a few globally established players such as F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Enzo Biochem, Inc. (US), Charles River Laboratories International, Inc. (US), and Eurofins Scientific (Luxembourg).
Scope of the report
|
Report Metric |
Details |
|
Market Size Available for Years |
2019–2026 |
|
Base Year Considered |
2020 |
|
Forecast Period |
2021–2026 |
|
Forecast Units |
Value (USD Billion) |
|
Segments Covered |
Product & Service, Type, Application, Disease Indication, and Region |
|
Geographies Covered |
North America, Europe, APAC, and RoW |
|
Companies Covered |
The major market players include F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Enzo Biochem, Inc. (US), Charles River Laboratories International, Inc. (US), and Eurofins Scientific (Luxembourg).
|
The study categorizes the biomarkers market into the following segments and subsegments:
Biomarkers Market, by Product
- Consumables
- Services
- Software
Biomarkers Market, by Type
- Safety Biomarkers
- Efficacy Biomarkers
- Predictive Biomarkers
- Surrogate Biomarkers
- Pharmacodynamics Biomarkers
- Prognostic Biomarkers
- Validation Biomarkers
Biomarkers Market, by Application
- Diagnostics
- Drug Discovery & Development
- Personalized Medicine
- Disease Risk Assessment
- Other Applications
Biomarkers Market, by Disease Indication
- Cancer by Test Type
- Solid biopsy
- Liquid Biopsy
- Infectious Diseases
- Immune Disorders
- Neurological Disorders
- Cardiovascular Disorders
- Other Disease Indications
Biomarkers Market, by Region
- North America
- US
- Canada
- Europe
- Germany
- UK
- France
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Rest of the World
- Latin America
- The Middle East and Africa
Recent Developments
- In April 2021, F. Hoffmann-La Roche Ltd. (Switzerland) launched two cardiac biomarker tests for high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These gold standard biomarkers support cardiovascular disease management and can help clinicians diagnose heart attacks and manage heart failure better.
- In May 2021, QIAGEN N.V. (Netherlands) launched the first FDA-approved tissue companion diagnostic, therascreen KRAS RGQ PCR Kit, to identify the KRAS G12C mutation in NSCLC tumors and expand precision medicine options in lung cancer.
- In July 2020, Thermo Fisher Scientific (US) entered into an agreement with Chugai Pharmaceutical to expand the use of the Oncomine Dx Target Test and expedite local biomarker testing of non-small cell lung cancer (NSCLC) patients eligible for ROZLYTREK (entrectinib) treatment in Japan.
- In January 2020, Merck KGaA (Germany) opened a non-profit, high-tech skill development center in collaboration with the Council of Scientific and Industrial Research’s Institute of Microbial Technology (CSIR-IMTECH) in Chandigarh, India. The center is equipped with genome-editing, single-molecule biomarker detection, and other technologies to help local students build life science skills.
- In April 2019, PerkinElmer, Inc. (US) acquired Cisbio Bioassays, a leading life sciences company that develops, manufactures, and markets high-quality kits and reagents for the drug discovery and life science markets. This acquisition complements PerkinElmer’s Alpha, DELFIA and LANCE assay technologies, including biomarker assays.
Frequently Asked Questions (FAQ):
What is the current size of the global biomarkers market?
The global biomarkers market is expected to reach USD 78.1 billion in 2026 from USD 43.1 billion in 2021 at a CARG of 12.6% during the forecast period.
Who are the leading players in the biomarkers market?
Leading players operating in the biomarkers market are F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Enzo Biochem, Inc. (US), Charles River Laboratories International, Inc. (US), and Eurofins Scientific (Luxembourg).
What are the major application segments of the biomarkers market?
Based on application, the biomarkers market is segmented into diagnostics, drug discovery & development, personalized medicine, disease risk assessment, and other applications. In 2020, the diagnostics segment accounted for the largest share of the application segment in the biomarkers market. The use of biomarkers for the diagnosis of multiple diseases, including cancer, infectious diseases, cardiovascular disorders, and neurological disorders, is on the rise. The increasing use of biomarkers is a major factor that drives the growth of the diagnostics segment of the biomarkers market.
What are the major drivers of the biomarkers market?
Growth in the biomarkers market is mainly driven by factors such as the growing importance of companion diagnostics, increasing prevalence of cancer worldwide, growing funding activities for biomarker research, and product innovations. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 31)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 BIOMARKERS MARKET SEGMENTATION
1.3.2 YEARS CONSIDERED IN THE REPORT
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 36)
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 PRIMARY SOURCES
FIGURE 4 BIOMARKERS MARKET: BREAKDOWN OF PRIMARIES
2.1.2.1 Key industry insights
2.2 MARKET SIZE ESTIMATION
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2020
FIGURE 6 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF ALL BIOMARKERS PRODUCTS
FIGURE 7 BIOMARKERS MARKET: CAGR PROJECTIONS, 2021–2026
FIGURE 8 BIOMARKERS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS OPPORTUNITIES, AND CHALLENGES
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH LIMITATIONS
2.5 RESEARCH ASSUMPTIONS
2.6 RISK ANALYSIS
3 EXECUTIVE SUMMARY (Page No. - 47)
FIGURE 10 BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD BILLION)
FIGURE 11 BIOMARKERS MARKET SHARE, BY TYPE, 2020
FIGURE 12 BIOMARKERS MARKET, BY DISEASE INDICATION, 2021 VS. 2026 (USD BILLION)
FIGURE 13 BIOMARKERS MARKET, BY APPLICATION, 2021−2026
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF THE BIOMARKERS MARKET
4 PREMIUM INSIGHTS (Page No. - 51)
4.1 BIOMARKERS MARKET OVERVIEW
FIGURE 15 THE GROWING IMPORTANCE OF COMPANION DIAGNOSTICS IS A KEY FACTOR EXPECTED TO DRIVE THE GROWTH OF THE BIOMARKERS MARKET
4.2 ASIA PACIFIC: BIOMARKERS MARKET, BY PRODUCT & COUNTRY (2020)
FIGURE 16 CONSUMABLES ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2020
4.3 EFFICACY BIOMARKERS MARKET, BY TYPE, 2020
FIGURE 17 THE PREDICTIVE BIOMARKERS SEGMENT IS PROJECTED TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 54)
5.1 MARKET DYNAMICS
FIGURE 18 BIOMARKERS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.1.1 MARKET DRIVERS
5.1.1.1 The growing importance of companion diagnostics
TABLE 1 RECENT DEVELOPMENTS IN COMPANION DIAGNOSTICS
5.1.1.2 Increasing prevalence of cancer worldwide
TABLE 2 GLOBAL CANCER INCIDENCE, 2020 VS. 2040
TABLE 3 LIST OF FDA-APPROVED BIOMARKERS FOR DIFFERENT TYPES OF CANCER
5.1.1.3 Increasing funds & grants for biomarker research
5.1.1.4 Continuous product innovations
TABLE 4 PRODUCT LAUNCHES, 2018−2021
5.1.2 RESTRAINTS
5.1.2.1 High capital investments and lengthy timelines for biomarker development
TABLE 5 TIMEFRAME FOR BIOMARKER DEVELOPMENT
5.1.3 OPPORTUNITIES
5.1.3.1 Personalized medicine
FIGURE 19 PERCENTAGE OF ONCOLOGY TRIALS INCORPORATING BIOMARKERS
TABLE 6 BIOMARKERS OF CARDIOVASCULAR DISEASE (CVD)
5.1.3.2 Emerging economies
5.1.4 CHALLENGES
5.1.4.1 Challenges associated with biomarker validation
5.1.4.2 Technical issues related to sample collection & storage
5.2 IMPACT OF COVID-19 ON THE BIOMARKERS MARKET
5.3 REGULATORY ASSESSMENT
5.3.1 INTRODUCTION
5.3.2 BIOMARKER QUALIFICATION IN THE US
5.3.3 BIOMARKER QUALIFICATION IN THE EU
5.3.4 BIOMARKER ACCEPTANCE IN DRUG DEVELOPMENT IN THE EU AND THE US
5.3.5 METHOD: EMA APPROVALS
5.3.6 METHOD: FDA APPROVALS
5.3.7 COMPANION DIAGNOSTICS
5.4 VALUE CHAIN ANALYSIS
FIGURE 20 BIOMARKERS MARKET: VALUE CHAIN ANALYSIS
5.5 TECHNOLOGICAL ANALYSIS
5.5.1 IMMUNOASSAYS
5.5.1.1 Immunohistochemistry (IHC)
5.5.1.2 Flow cytometry
5.5.1.3 Flow cytometry ELISA
5.5.2 NEXT-GENERATION SEQUENCING (NGS)
5.5.3 POLYMERASE CHAIN REACTION (PCR)
5.5.4 IN SITU HYBRIDIZATION
5.5.5 MICROARRAYS
5.5.6 MASS SPECTROMETRY
5.6 PORTER’S FIVE FORCES ANALYSIS
TABLE 7 BIOMARKERS MARKET- PORTER’S FIVE FORCES ANALYSIS
5.6.1 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS
5.6.2 BARGAINING POWER OF SUPPLIERS
5.6.3 BARGAINING POWER OF BUYERS
5.6.4 THREAT OF SUBSTITUTES
5.6.5 THREAT OF NEW ENTRANTS
5.7 PATENT ANALYSIS
5.7.1 NUMBER OF PUBLICATIONS OVER LAST 10 YEARS
5.7.2 TOP 20 GRANTED PATENT OWNERS (US) IN LAST 20 YEARS
5.7.3 TOP 10 PLAYERS WITH HIGHEST NO. OF PATENT APPLICATIONS
5.7.4 LIST OF RECENT PATENTS
5.8 SUPPLY CHAIN ANALYSIS
FIGURE 21 DIRECT DISTRIBUTION STRATEGY PREFERRED BY PROMINENT COMPANIES
5.8.1 KEY INFLUENCERS
5.9 ECOSYSTEM ANALYSIS OF THE BIOMARKERS MARKET
FIGURE 22 ECOSYSTEM ANALYSIS OF THE BIOMARKERS MARKET
5.9.1 ROLE IN THE ECOSYSTEM
5.10 Y.C., YCC SHIFT
FIGURE 23 YC-YCC SHIFT FOR THE BIOMARKERS MARKET
5.11 RANGES/ SCENARIOS
FIGURE 24 DEPENDING ON HOW THE UNCERTAINTIES UNFOLD, WE SEE A SPECTRUM OF SCENARIOS FOR THE BIOMARKERS MARKET – 2020
6 BIOMARKERS MARKET, BY PRODUCT & SERVICE (Page No. - 79)
6.1 INTRODUCTION
TABLE 8 BIOMARKERS MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD BILLION)
6.2 CONSUMABLES
6.2.1 THE HIGHER FREQUENCY OF REPEATED PURCHASES OF CONSUMABLES TO DRIVE THE MARKET GROWTH
TABLE 9 BIOMARKER CONSUMABLES MARKET, BY REGION, 2019–2026 (USD BILLION)
TABLE 10 NORTH AMERICA: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 11 EUROPE: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 12 ASIA PACIFIC: BIOMARKER CONSUMABLES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.3 SERVICES
6.3.1 THE GRADUAL SHIFT FROM IN-HOUSE BIOMARKER TESTING TO OUTSOURCING OF SERVICES IS EXPECTED TO SUPPORT MARKET GROWTH
TABLE 13 BIOMARKER SERVICES MARKET, BY REGION, 2019–2026 (USD BILLION)
TABLE 14 NORTH AMERICA: BIOMARKER SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 15 EUROPE: BIOMARKER SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 16 ASIA PACIFIC: BIOMARKER SERVICES MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
6.4 SOFTWARE
6.4.1 INCREASING ADOPTION OF BIOINFORMATICS TOOLS BY PHARMACEUTICAL COMPANIES TO SUPPORT THE MARKET GROWTH
TABLE 17 BIOMARKER SOFTWARE MARKET, BY REGION, 2019–2026 (USD BILLION)
TABLE 18 NORTH AMERICA: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 19 EUROPE: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 20 ASIA PACIFIC: BIOMARKER SOFTWARE MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
7 BIOMARKERS MARKET, BY TYPE (Page No. - 86)
7.1 INTRODUCTION
TABLE 21 BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
7.2 EFFICACY BIOMARKERS
TABLE 22 EFFICACY BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 23 EFFICACY BIOMARKERS MARKET, BY REGION, 2019–2026 (USD BILLION)
TABLE 24 NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 25 EUROPE: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 26 ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
7.2.1 PREDICTIVE BIOMARKERS
7.2.1.1 Wide applications of predictive biomarkers in personalized medicine and companion diagnostics drive the growth of this segment
TABLE 27 PREDICTIVE BIOMARKERS MARKET, BY REGION, 2019–2026 (USD BILLION)
TABLE 28 NORTH AMERICA: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 29 EUROPE: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 30 ASIA PACIFIC: PREDICTIVE BIOMARKERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
7.2.2 SURROGATE BIOMARKERS
7.2.2.1 The use of surrogate biomarkers helps accelerate drug development and shorten timelines for regulatory approval
TABLE 31 SURROGATE BIOMARKERS MARKET, BY REGION, 2019–2026 (USD BILLION)
TABLE 32 NORTH AMERICA: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 33 EUROPE: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 34 ASIA PACIFIC: SURROGATE BIOMARKERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
7.2.3 PHARMACODYNAMIC BIOMARKERS
7.2.3.1 Increasing utilization of pharmacodynamic biomarkers in the selection & optimization of drug doses supports segment growth
TABLE 35 PHARMACODYNAMIC BIOMARKERS MARKET, BY REGION, 2019–2026 (USD BILLION)
TABLE 36 NORTH AMERICA: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 37 . EUROPE: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 38 ASIA PACIFIC: PHARMACODYNAMIC BIOMARKERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
7.2.4 PROGNOSTIC BIOMARKERS
7.2.4.1 Prognostic biomarkers help in predicting the recurrence of diseases
TABLE 39 PROGNOSTIC BIOMARKERS MARKET, BY REGION, 2019–2026 (USD BILLION)
TABLE 40 NORTH AMERICA: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 41 EUROPE: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 42 ASIA PACIFIC: PROGNOSTIC BIOMARKERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
7.3 SAFETY BIOMARKERS
7.3.1 WIDE APPLICATIONS OF SAFETY BIOMARKERS IN DRUG DISCOVERY & DEVELOPMENT IS EXPECTED TO FUEL MARKET GROWTH
TABLE 43 SAFETY BIOMARKERS MARKET, BY REGION, 2019–2026 (USD BILLION)
TABLE 44 NORTH AMERICA: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 45 EUROPE: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 46 ASIA PACIFIC: SAFETY BIOMARKERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
7.4 VALIDATION BIOMARKERS
7.4.1 VALIDATION BIOMARKERS ENABLE IN THE EVALUATION OF DIAGNOSTIC SYSTEMS
TABLE 47 VALIDATION BIOMARKERS MARKET, BY REGION, 2019–2026 (USD BILLION)
TABLE 48 NORTH AMERICA: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 49 EUROPE: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 50 ASIA PACIFIC: VALIDATION BIOMARKERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
8 BIOMARKERS MARKET, BY DISEASE INDICATION (Page No. - 100)
8.1 INTRODUCTION
TABLE 51 BIOMARKERS MARKET, BY DISEASE INDICATION, 2019–2026 (USD BILLION)
8.2 CANCER
8.2.1 INCREASING ADOPTION OF BIOMARKERS IN CANCER RESEARCH & DIAGNOSIS IS EXPECTED TO DRIVE THE MARKET GROWTH
TABLE 52 LIST OF FDA-APPROVED BIOMARKERS FOR CANCER
TABLE 53 BIOMARKERS MARKET FOR CANCER, BY REGION, 2019–2026 (USD BILLION)
TABLE 54 NORTH AMERICA: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 55 EUROPE: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 56 ASIA PACIFIC: BIOMARKERS MARKET FOR CANCER, BY COUNTRY, 2019–2026 (USD BILLION)
8.2.2 SOLID BIOPSY
8.2.2.1 Solid biopsy provides the mutations from within the tumors
8.2.3 LIQUID BIOPSY
8.2.3.1 A liquid biopsy helps detect circulating tumor cells
TABLE 57 CANCER DISEASE INDICATION MARKET, BY TEST TYPE, 2019–2026 (USD BILLION)
8.3 INFECTIOUS DISEASES
8.3.1 THE INCREASING PREVALENCE OF INFECTIOUS DISEASES ARE EXPECTED TO INCREASE THE DEMAND FOR BIOMARKERS
TABLE 58 BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2019–2026 (USD BILLION)
TABLE 59 NORTH AMERICA: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 60 EUROPE: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 61 ASIA PACIFIC: BIOMARKERS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD BILLION)
8.4 IMMUNOLOGICAL DISORDERS
8.4.1 INCREASING ADOPTION OF BIOMARKERS FOR VARIOUS IMMUNOLOGICAL DISORDERS ARE EXPECTED TO DRIVE THE MARKET GROWTH
TABLE 62 BIOMARKERS FOR IMMUNOLOGICAL DISORDERS
TABLE 63 BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2019–2026 (USD BILLION)
TABLE 64 NORTH AMERICA: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 65 EUROPE: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 66 ASIA PACIFIC: BIOMARKERS MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2019–2026 (USD BILLION)
8.5 NEUROLOGICAL DISORDERS
8.5.1 IMMUNOASSAYS ARE WIDELY USED IN THE DIAGNOSIS OF NEUROLOGICAL DISORDERS
TABLE 67 BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2019–2026 (USD BILLION)
TABLE 68 NORTH AMERICA: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 69 EUROPE: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 70 ASIA PACIFIC: BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2019–2026 (USD BILLION)
8.6 CARDIOVASCULAR DISORDERS
8.6.1 THE INCREASING PREVALENCE OF CVD IS EXPECTED TO INCREASE THE DEMAND FOR CARDIAC BIOMARKERS
TABLE 71 BIOMARKERS FOR CARDIOVASCULAR DISORDERS
TABLE 72 BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY REGION, 2019–2026 (USD BILLION)
TABLE 73 NORTH AMERICA: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 74 EUROPE: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 75 ASIA PACIFIC: BIOMARKERS MARKET FOR CARDIOVASCULAR DISORDERS, BY COUNTRY, 2019–2026 (USD BILLION)
8.7 OTHER DISEASE INDICATIONS
TABLE 76 BIOMARKERS FOR RENAL DISORDERS
TABLE 77 ENDOCRINE BIOMARKERS
TABLE 78 BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2019–2026 (USD BILLION)
TABLE 79 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 80 EUROPE: BIOMARKERS MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 81 ASIA PACIFIC: BIOMARKERS MARKET SIZE FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2019–2026 (USD BILLION)
9 BIOMARKERS MARKET, BY APPLICATION (Page No. - 116)
9.1 INTRODUCTION
TABLE 82 BIOMARKERS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
9.2 DIAGNOSTICS
9.2.1 THE INCREASING USE OF BIOMARKERS FOR THE DIAGNOSIS OF VARIOUS DISEASES TO DRIVE THE GROWTH OF THIS APPLICATION SEGMENT
TABLE 83 BIOMARKERS MARKET FOR DIAGNOSTICS, BY REGION, 2019–2026 (USD BILLION)
TABLE 84 NORTH AMERICA: BIOMARKERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 85 EUROPE: BIOMARKERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 86 ASIA PACIFIC: BIOMARKERS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2019–2026 (USD BILLION)
9.3 DRUG DISCOVERY & DEVELOPMENT
9.3.1 BIOMARKERS PLAY A KEY ROLE AS BIOLOGICAL INDICATORS IN THE DEVELOPMENT OF NEW DRUGS
TABLE 87 BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2019–2026 (USD BILLION)
TABLE 88 NORTH AMERICA: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 89 EUROPE: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 90 ASIA PACIFIC: BIOMARKERS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2019–2026 (USD BILLION)
9.4 PERSONALIZED MEDICINE
9.4.1 INCREASING APPLICATIONS OF BIOMARKERS IN PERSONALIZED MEDICINE FOR TARGETED THERAPIES DRIVES THE MARKET GROWTH
TABLE 91 SELECTED PERSONALIZED MEDICINE DRUGS AND RELEVANT BIOMARKERS
TABLE 92 BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2019–2026 (USD BILLION)
TABLE 93 NORTH AMERICA: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 94 EUROPE: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 95 ASIA PACIFIC: BIOMARKERS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2019–2026 (USD BILLION)
9.5 DISEASE RISK ASSESSMENT
9.5.1 BIOMARKERS ARE WIDELY USED FOR THE CHARACTERIZATION OF TOXICITY IN DISEASE DIAGNOSIS & DRUG DEVELOPMENT PROCESSES
TABLE 96 BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT, BY REGION, 2019–2026 (USD BILLION)
TABLE 97 NORTH AMERICA: BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 98 EUROPE: BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 99 ASIA PACIFIC: BIOMARKERS MARKET FOR DISEASE RISK ASSESSMENT, BY COUNTRY, 2019–2026 (USD BILLION)
9.6 OTHER APPLICATIONS
TABLE 100 BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY REGION, 2019–2026 (USD BILLION)
TABLE 101 NORTH AMERICA: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 102 EUROPE: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 103 ASIA PACIFIC: BIOMARKERS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD BILLION)
10 BIOMARKERS MARKET, BY REGION (Page No. - 127)
10.1 INTRODUCTION
TABLE 104 BIOMARKERS MARKET, BY REGION, 2019–2026 (USD BILLION)
10.2 NORTH AMERICA
FIGURE 25 NORTH AMERICA: MARKET SNAPSHOT
TABLE 105 NORTH AMERICA: BIOMARKERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 106 NORTH AMERICA: BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 107 NORTH AMERICA: BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 108 NORTH AMERICA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 109 NORTH AMERICA: BIOMARKERS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 110 NORTH AMERICA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019–2026 (USD BILLION)
10.2.1 US
10.2.1.1 The US is expected to dominate the biomarkers market in North America during the forecast period
TABLE 111 US.: BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 112 US: BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 113 US: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 114 US: BIOMARKERS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 115 US: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019–2026 (USD BILLION)
10.2.2 CANADA
10.2.2.1 The increasing incidence of cancer drives the growth of biomarker research in Canada
TABLE 116 CANADA: BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 117 CANADA: BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 118 CANADA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 119 CANADA: BIOMARKERS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 120 CANADA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019–2026 (USD BILLION)
10.3 EUROPE
TABLE 121 EUROPE: BIOMARKERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 122 EUROPE: BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 123 EUROPE: BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 124 EUROPE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 125 EUROPE: BIOMARKERS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 126 EUROPE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019–2026 (USD BILLION)
10.3.1 GERMANY
10.3.1.1 Increasing government funding for biomarker research drives the market growth in Germany
TABLE 127 GERMANY: BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 128 GERMANY: BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 129 GERMANY: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 130 GERMANY: BIOMARKERS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 131 GERMANY: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019–2026 (USD BILLION)
10.3.2 UK
10.3.2.1 Availability of government funding and strategic collaborations with biotech firms have significantly boosted the adoption of biomarkers in the UK
TABLE 132 UK: BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 133 UK: BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 134 UK: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 135 UK: BIOMARKERS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 136 UK: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019–2026 (USD BILLION)
10.3.3 FRANCE
10.3.3.1 Increasing government investments in genomics & proteomics research to drive the market growth
TABLE 137 FRANCE: BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 138 FRANCE: BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 139 FRANCE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 140 FRANCE: BIOMARKERS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 141 FRANCE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019–2026 (USD BILLION)
10.3.4 REST OF EUROPE (ROE)
TABLE 142 ROE: BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 143 ROE: BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 144 ROE: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 145 ROE: BIOMARKERS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 146 ROE: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019–2026 (USD BILLION)
10.4 ASIA PACIFIC
FIGURE 26 ASIA PACIFIC: MARKET SNAPSHOT
TABLE 147 ASIA PACFIC: BIOMARKERS MARKET, BY COUNTRY, 2019–2026 (USD BILLION)
TABLE 148 ASIA PACIFIC: BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 149 ASIA PACIFIC: BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 150 ASIA PACIFIC: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 151 ASIA PACIFIC: BIOMARKERS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 152 ASIA PACIFIC: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019–2026 (USD BILLION)
10.4.1 CHINA
10.4.1.1 The increasing burden of diseases and growing focus on the development of novel drugs are expected to drive the demand for biomarkers in China
TABLE 153 CHINA: BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 154 CHINA: BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 155 CHINA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 156 CHINA: BIOMARKERS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 157 CHINA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019–2026 (USD BILLION)
10.4.2 JAPAN
10.4.2.1 Strategic collaborations with leading pharmaceutical companies drive the market growth in Japan
TABLE 158 JAPAN: BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 159 JAPAN: BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 160 JAPAN: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 161 JAPAN: BIOMARKERS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 162 JAPAN: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019–2026 (USD BILLION)
10.4.3 INDIA
10.4.3.1 The growing prevalence of target diseases is expected to support the biomarkers market in India
TABLE 163 INDIA: BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 164 INDIA: BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 165 INDIA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 166 INDIA: BIOMARKERS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 167 INDIA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019–2026 (USD BILLION)
10.4.4 REST OF ASIA PACIFIC (ROAPAC)
TABLE 168 ROAPAC: BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 169 ROAPAC: BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 170 ROAPAC: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 171 ROAPAC: BIOMARKERS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 172 ROAPAC: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019–2026 (USD BILLION)
10.5 REST OF THE WORLD (ROW)
TABLE 173 ROW: BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 174 ROW: BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 175 ROW: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 176 ROW: BIOMARKERS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 177 ROW: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019–2026 (USD BILLION)
10.5.1 LATIN AMERICA (LATAM)
10.5.1.1 Availability of research funding and the rising awareness of advanced sequencing technologies drives the market growth in LATAM
TABLE 178 LATAM: BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 179 LATAM: BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 180 LATAM: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 181 LATAM: BIOMARKERS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 182 LATAM: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019–2026 (USD BILLION)
10.5.2 MIDDLE EAST AND AFRICA (MEA)
10.5.2.1 Increasing focus on proteomics & genomics research supports market growth in the MEA
TABLE 183 MEA: BIOMARKERS MARKET, BY PRODUCT, 2019–2026 (USD BILLION)
TABLE 184 MEA: BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 185 MEA: EFFICACY BIOMARKERS MARKET, BY TYPE, 2019–2026 (USD BILLION)
TABLE 186 MEA: BIOMARKERS MARKET, BY APPLICATION, 2019–2026 (USD BILLION)
TABLE 187 MEA: BIOMARKERS MARKET, BY DISEASE INDICATION, 2019–2026 (USD BILLION)
11 COMPETITIVE LANDSCAPE (Page No. - 167)
11.1 KEY PLAYER STRATEGIES
11.1.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY BIOMARKERS PLAYERS
11.2 MARKET SHARE ANALYSIS
FIGURE 27 BIOMARKERS MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS, 2020
TABLE 188 BIOMARKERS MARKET: DEGREE OF COMPETITION
11.3 REVENUE ANALYSIS
FIGURE 28 REVENUE ANALYSIS FOR KEY COMPANIES (2017-2020)
11.4 COMPANY EVALUATION QUADRANT
FIGURE 29 BIOMARKERS MARKET (GLOBAL) COMPANY EVALUATION MATRIX, 2020
11.4.1 STAR
11.4.2 PERVASIVE
11.4.3 EMERGING LEADER
11.4.4 PARTICIPANT
11.5 COMPETITIVE LEADERSHIP MAPPING (START-UPS) (2020)
11.5.1 PROGRESSIVE COMPANIES
11.5.2 STARTING BLOCKS
11.5.3 DYNAMIC COMPANIES
11.5.4 RESPONSIVE COMPANIES
FIGURE 30 COMPETITIVE LEADERSHIP MAPPING: BIOMARKERS MARKET
11.5.4.1 COMPETITIVE BENCHMARKING
TABLE 189 COMPANY PRODUCT FOOTPRINT (25 COMPANIES)
TABLE 190 COMPANY APPLICATION FOOTPRINT (25 COMPANIES)
TABLE 191 COMPANY REGION FOOTPRINT (25 COMPANIES)
TABLE 192 COMPANY FOOTPRINT (25 COMPANIES)
11.6 COMPETITIVE SCENARIO
11.6.1 PRODUCT LAUNCHES
TABLE 193 BIOMARKERS MARKET: PRODUCT LAUNCHES, JANUARY 2018-MAY 2021
11.6.2 DEALS
TABLE 194 BIOMARKERS MARKET: DEALS, JANUARY 2018-MAY 2021
11.6.3 OTHERS
12 COMPANY PROFILES (Page No. - 184)
12.1 KEY COMPANIES
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 F. HOFFMANN-LA ROCHE LTD
TABLE 195 HOFFMANN-LA ROCHE LTD: BUSINESS OVERVIEW
FIGURE 31 COMPANY SNAPSHOT: HOFFMANN-LA ROCHE LTD (2020)
TABLE 196 HOFFMANN-LA ROCHE LTD: PRODUCT OFFERINGS
TABLE 197 HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES & APPROVALS
12.1.2 THERMO FISHER SCIENTIFIC INC.
TABLE 198 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
FIGURE 32 COMPANY SNAPSHOT: THERMO FISHER SCIENTIFIC INC (2020)
TABLE 199 THERMO FISHER SCIENTIFIC INC.: PRODUCT/SERVICE OFFERINGS
TABLE 200 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES & APPROVALS
TABLE 201 THERMO FISHER SCIENTIFIC INC.: DEALS
TABLE 202 THERMO FISHER SCIENTIFIC INC.: OTHERS
12.1.3 ABBOTT LABORATORIES
TABLE 203 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 33 COMPANY SNAPSHOT: ABBOTT LABORATORIES (2020)
TABLE 204 ABBOTT LABORATORIES: PRODUCT OFFERINGS
TABLE 205 ABBOTT LABORATORIES: PRODUCT LAUNCHES
12.1.4 QIAGEN N.V.
TABLE 206 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 34 COMPANY SNAPSHOT: QIAGEN N.V. (2020)
TABLE 207 QIAGEN N.V.: PRODUCT/SERVICE OFFERINGS
TABLE 208 QIAGEN N.V.: PRODUCT LAUNCHES
TABLE 209 QIAGEN N.V.: DEALS
12.1.5 PERKINELMER, INC.
TABLE 210 PERKINELMER, INC.: BUSINESS OVERVIEW
FIGURE 35 COMPANY SNAPSHOT: PERKINELMER, INC. (2020)
TABLE 211 PERKINELMER, INC.: PRODUCT/SERVICE OFFERINGS
TABLE 212 PERKINELMER, INC.: DEALS
12.1.6 MERCK KGAA
TABLE 213 MERCK KGAA.: BUSINESS OVERVIEW
FIGURE 36 COMPANY SNAPSHOT: MERCK KGAA (2020)
TABLE 214 MERCK KGAA: PRODUCT/SERVICE OFFERINGS
TABLE 215 MERK KGAA: DEALS
TABLE 216 MERCK KGAA: OTHERS
12.1.7 BIO-RAD LABORATORIES, INC.
TABLE 217 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 37 COMPANY SNAPSHOT: BIO-RAD LABORATORIES, INC. (2020)
TABLE 218 BIO-RAD LABORATORIES, INC.: PRODUCT OFFERINGS
12.1.8 ENZO BIOCHEM, INC.
TABLE 219 ENZO BIOCHEM, INC.: BUSINESS OVERVIEW
FIGURE 38 COMPANY SNAPSHOT: ENZO BIOCHEM, INC. (2020)
TABLE 220 ENZO BIOCHEM, INC.: PRODUCT OFFERINGS
TABLE 221 ENZO BIOCHEM, INC.: OTHERS
12.1.9 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
TABLE 222 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS OVERVIEW
FIGURE 39 COMPANY SNAPSHOT: CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (2020)
TABLE 223 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: SERVICE OFFERINGS
12.1.10 EUROFINS SCIENTIFIC
TABLE 224 EUROFINS SCIENTIFIC.: BUSINESS OVERVIEW
FIGURE 40 COMPANY SNAPSHOT: EUROFINS SCIENTIFIC (2020)
TABLE 225 EUROFINS SCIENTIFIC: SERVICE OFFERINGS
12.1.11 MESO SCALE DIAGNOSTICS, LLC.
TABLE 226 MESO SCALE DIAGNOSTICS, LLC.: BUSINESS OVERVIEW
TABLE 227 MESO SCALE DIAGNOSTICS, LLC: PRODUCT/SERVICE OFFERINGS
12.1.12 STRESSMARQ BIOSCIENCES INC.
TABLE 228 STRESSMARQ BIOSCIENCES INC.: BUSINESS OVERVIEW
TABLE 229 STRESSMARQ BIOSCIENCES INC.: PRODUCT OFFERINGS
12.1.13 DIAMETRA
TABLE 230 DIAMETRA: BUSINESS OVERVIEW
TABLE 231 DIAMETRA: PRODUCT OFFERINGS
12.1.14 SIGNOSIS, INC.
TABLE 232 SIGNOSIS, INC.: BUSINESS OVERVIEW
12.1.15 PRODUCTS OFFERED
TABLE 233 SIGNOSIS, INC.: PRODUCT OFFERINGS
12.2 OTHER COMPANIES
12.2.1 BIOMÉRIEUX SA
TABLE 234 BIOMÉRIEUX SA: COMPANY OVERVIEW
12.2.2 AXON MEDCHEM BV
TABLE 235 AXON MEDCHEM BV: COMPANY OVERVIEW
12.2.3 EKF DIAGNOSTICS HOLDINGS, PLC
TABLE 236 EKF DIAGNOSTICS HOLDINGS, PLC: COMPANY OVERVIEW
12.2.4 MICROCONSTANTS, INC.
TABLE 237 MICROCONSTANTS, INC.: COMPANY OVERVIEW
12.2.5 NORTHEAST BIOANALYTICAL LABORATORIES LLC.
TABLE 238 NORTHEAST BIOANALYTICAL LABORATORIES LLC.: COMPANY OVERVIEW
12.2.6 Q2 SOLUTIONS LLC
TABLE 239 Q2 SOLUTIONS LLC: COMPANY OVERVIEW
12.2.7 JSR LIFE SCIENCES, LLC
TABLE 240 JSR LIFE SCIENCES, LLC: COMPANY OVERVIEW
12.2.8 BIOAGILYTIX LABS
TABLE 241 BIOAGILYTIX LABS.: COMPANY OVERVIEW
12.2.9 CELERION
TABLE 242 CELERION: COMPANY OVERVIEW
12.2.10 ANYGENES
TABLE 243 ANYGENES: COMPANY OVERVIEW
12.2.11 BIOMARKERBAY B. V.
TABLE 244 BIOMARKERBAY: COMPANY OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 232)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
This market research study involved the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global biomarkers market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify critical qualitative and quantitative information and assess market growth prospects. The global size of the biomarkers market (estimated through various secondary research approaches) was then triangulated with primary research inputs to arrive at the final market size.
Secondary Research
The secondary sources referred to for this research study include publications from organizations such as the World Bank, GLOBOCAN, World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Cancer Institute, Food and Drug Administration (FDA), European Medicines Agency, National Comprehensive Cancer Network (NCCN), The European Association for Cancer Research (EACR), Australian Cancer Research Foundation (ACRF), and National Institutes of Health (NIH).
Secondary sources also include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global biomarkers market, which was validated through primary research.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global biomarkers market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand-side (such as personnel from pharmaceutical & biotechnology companies, academia, research, and CROs) and supply-side (such as C-level and D-level executives, product managers, and marketing and sales managers of key manufacturers, distributors, and channel partners from tier 1 and tier 2 companies offering biomarkers) across five major regions—North America, Europe, the Asia Pacific, and the Rest of the World (Latin America & the Middle East & Africa). Approximately 70% and 30% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
To know about the assumptions considered for the study, download the pdf brochure
Data Triangulation
After arriving at the overall size of the biomarkers market through the methodology mentioned above, this market was split into several segments and subsegments. Market breakdown procedures were employed, wherever applicable, to arrive at the exact market value for the key segments and subsegments. The extrapolated market data was triangulated by studying various macroindicators and regional trends from both demand and supply-side participants.
Report Objectives
- To define, describe, and forecast the global biomarkers market on the basis of product & service, type, application, disease indication, and region
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets and subsegments with respect to individual growth trends, future prospects, and contributions to the overall biomarkers market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To profile the key players in the global biomarkers market and comprehensively analyze their core competencies and market rankings
- To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW)
- To track and analyze competitive developments such as acquisitions, new product developments & approvals, agreements, partnerships and collaborations in the biomarkers market
Available Customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographic Analysis
- Further breakdown of the European biomarkers market into RoE countries
- Further breakdown of the Asia Pacific biomarkers market into RoAPAC countries
Company Information
- Detailed analysis and profiling of additional market players (up to 5)
Get in-depth analysis of the COVID-19 impact on the Biomarkers Market
Benchmarking the rapid strategy shifts of the Top 100 companies in the Biomarkers Market
Request For Special Pricing
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Biomarkers Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Biomarkers Market